INSULIN DETEMIR IMPROVES GLYCEMIC CONTROL AND IS WEIGHT NEUTRALIN THE SLOVENIAN COHORT OF THE PREDICTIVE™ STUDY – CLINICALEXPERIENCE IN SLOVENIA
Abstract
BACKGROUND The PREDICTIVE™ study is a large, multinational, multi-centre, observational studyassessing the safety and efficacy of insulin detemir in everyday clinical practice.Patients and methods The Slovenian cohort included 303 patients, with 268 (78 Type 1, 181 Type 2)patients eligible for the final analysis. The analysis was performed 12 weeks afterswitching the patients to insulin detemir, and evaluated: characteristics of the antidiabetictherapy (ATh; including OAD and number of daily injections), safety (total, severe andnocturnal hypoglycaemic events), efficacy (HbA1c and FBG levels, FBG variability), andeffect on body weight. RESULTS As for the ATh, the main shift was observed from premix regimens to more complex insulinregimens, and from OAD regimens to insulin therapy. Statistically significant reductionsof total, severe and nocturnal hypoglycaemic events were observed in both groups (Type 1:from 4.4 %, 0.38 % and 1.11 % at the baseline to 1.8 %, 0.01 % and 0.24 % at the end; Type2: from 2.3 %, 0.2 % and 0.89 % at the baseline to 0.7 %, 0.03 % and 0.2 % at the end,respectively; all p values < 0.001). Statistically significant reductions of HbA1c and FBGlevels were also observed (Type 1: HbA1c from 8.11 % to 7.63 %, FBG from 8.9 mmol/Lto 7.4 mmol/L; Type 2: HbA1c from 8.72 % to 8.06 %, FBG from 9.4 mmol/L to 8.0 mmol/L;all p values < 0.001). FBG variability (as measured by the average standard deviation)decreased from 2.33 mmol/L and 1.58 mmol/L to 1.86 mmol/L and 1.32 mmol/L in Type 1and Type 2, respectively; both p values < 0.05). An overall trend toward weight loss wasnoted at week 12 (Type 1: –0.3 kg, NS; Type 2: –0.4 kg, p < 0.05). CONCLUSIONS The Slovenian cohort data thus support the short-term safety and efficacy of insulin detemir in daily clinical practice. These results are consistent with the findings of controlledclinical trials, including essentially no effect on body weight gainDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.